Xen45 gel implant for micro-invasive glaucoma surgery (migs)

12-18-2020 | Innovations technologiques et dispositifs médicaux

Glaucoma refers to a group of chronic, progressive optical neuropathies that cause an irreversible loss of visual field (VF) and that can ultimately lead to blindness. Advanced primary open-angle glaucoma (POAG) is the most common form, for which the XEN45 gel implant is currently used as treatment in Québec’s health-care system although with a limited access.

In light of the available information, INESSS is of the opinion that public coverage of the XEN45 gel implant could be a fair and reasonable decision if economic burden mitigation measures were put in place and their use governed by certain criteria.

REF650

Subscribe to our newsletter now

Subscription